Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 6:01 pm Sale | 13G | Ovid Therapeutics Inc. OVID | EcoR1 Capital LLC | 0 0.000% | -6,117,400 (Position Closed) | View |
| 2024-11-14 4:39 pm Sale | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% | -2,997,233 (-43.75%) | View |
| 2024-02-14 4:15 pm Sale | 13G | Ovid Therapeutics Inc. OVID | LEVIN JEREMY M | 6,942,181 9.400% | -338,940 (-4.66%) | View |
| 2024-02-14 11:10 am Purchase | 13G | Ovid Therapeutics Inc. OVID | Madison Avenue Partners LP | 3,648,509 5.200% | 39,455 (+1.09%) | View |
| 2024-02-12 06:06 am Sale | 13G | Ovid Therapeutics Inc. OVID | Rubric Capital Management LP | 5,315,969 7.520% | -1,512,096 (-22.15%) | View |
| 2024-01-29 5:25 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 4,319,918 6.100% | 3,117,188 (+259.18%) | View |
| 2023-07-31 5:21 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | Madison Avenue Partners LP | 3,609,054 5.100% | 3,609,054 (New Position) | View |
| 2023-02-14 4:01 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | LEVIN JEREMY M | 7,281,121 10.000% | 726,351 (+11.08%) | View |
| 2023-02-13 6:22 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 6,851,051 9.700% | 220,000 (+3.32%) | View |
| 2023-02-13 10:28 am Sale | 13G | Ovid Therapeutics Inc. OVID | Stonepine Capital Management LLC | 0 0.000% | -4,006,185 (Position Closed) | View |
| 2023-02-10 4:00 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | Rubric Capital Management LP | 6,828,065 9.690% | 6,828,065 (New Position) | View |
| 2023-02-10 2:28 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | EcoR1 Capital LLC | 6,117,400 8.700% | 35,200 (+0.58%) | View |
| 2023-02-09 11:30 am Sale | 13G | Ovid Therapeutics Inc. OVID | VANGUARD GROUP INC | 2,581,736 3.660% | -860,882 (-25.01%) | View |
| 2023-02-03 11:50 am Sale | 13G | Ovid Therapeutics Inc. OVID | TAKEDA PHARMACEUTICAL CO LTD TAK | 0 0.000% | -6,012,758 (Position Closed) | View |
| 2023-02-03 11:48 am Purchase | 13G | Ovid Therapeutics Inc. OVID | TAKEDA PHARMACEUTICAL CO LTD TAK | 8,781,996 12.200% | 1,250,000 (+16.60%) | View |
| 2022-02-14 5:29 pm Sale | 13G | Ovid Therapeutics Inc. OVID | During Matthew | 3,103,932 4.500% | -916,862 (-22.80%) | View |
| 2022-02-14 4:31 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | LEVIN JEREMY M | 6,554,770 9.400% | 462,500 (+7.59%) | View |
| 2022-02-14 3:21 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | EcoR1 Capital LLC | 6,082,200 8.900% | 6,082,200 (New Position) | View |
| 2022-02-11 5:47 pm Purchase | 13G | Ovid Therapeutics Inc. OVID | Stonepine Capital Management LLC | 4,006,185 5.900% | 506,185 (+14.46%) | View |
| 2022-02-10 08:32 am Purchase | 13G | Ovid Therapeutics Inc. OVID | VANGUARD GROUP INC | 3,442,618 5.060% | 3,442,618 (New Position) | View |